Maxim Keeps ContraVir Pharma (CTRV) at 'Buy' as CMX157 Progresses into Phase 2a for HBV
- Futures tread higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
CMX157 Advances Head-to-Head Phase 2a Clinical Study in Hepatitis B Patients with Favorable Recommendation from DSMB
October 17, 2016 6:00 AM EDTEDISON, N.J., Oct. 17, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that following a positive recommendation from an independent Data Safety Monitoring Board (DSMB), the company has begun enrolling the next dosing group in its head-to-head Phase 2a dose-escalation study comparing the safety and efficacy of ContraVir's CMX157 to tenofovir disoproxil fumarate (TDF, marketed by Gilead Sciences as Viread®) in patients with chronic hepatitis B (HBV). ContraVir expects to complete the remaining two escalation cohorts and... More
CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® in Hepatitis B Patients
October 13, 2016 6:00 AM EDTEDISON, N.J., Oct. 13, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead's Viread®) in chronically infected hepatitis B (HBV) patients.Â
Patients successfully completed both 5 mg and 10 mg cohorts, and interim data reported below... More